| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Additional lessons to prepare for rapid research response to possible vertical transmission of Oropouche virus in Brazil
|
Diniz, Debora
|
|
|
25 |
1 |
p. e9
|
artikel
|
| 2 |
Advancing the chemotherapy of tuberculous meningitis: a consensus view
|
Wasserman, Sean
|
|
|
25 |
1 |
p. e47-e58
|
artikel
|
| 3 |
Ana Bispo—from polio to Zika virus and beyond
|
Kirby, Tony
|
|
|
25 |
1 |
p. 21
|
artikel
|
| 4 |
Antimicrobial resistance among refugees and asylum seekers: a global systematic review and meta-analysis
|
Hermsen, Elizabeth D
|
|
|
25 |
1 |
p. e34-e43
|
artikel
|
| 5 |
A pox on all our houses: a missing component in the global mpox response is equity
|
Jonas, Eddy
|
|
|
25 |
1 |
p. e44-e46
|
artikel
|
| 6 |
BCG multifocal osteomyelitis
|
Li, Chongwei
|
|
|
25 |
1 |
p. e59
|
artikel
|
| 7 |
Burden of upper respiratory infections and otitis media
|
Marom, Tal
|
|
|
25 |
1 |
p. 3-5
|
artikel
|
| 8 |
Correction to Lancet Infect Dis 2025; 25: 36–51
|
|
|
|
25 |
1 |
p. e13
|
artikel
|
| 9 |
Correction to Lancet Infect Dis 2025; 25: e47–58
|
|
|
|
25 |
1 |
p. e13
|
artikel
|
| 10 |
Correction to Lancet Infect Dis 2024; published online October 7. https://doi.org/10.1016/S1473-3099(24)00561-9
|
|
|
|
25 |
1 |
p. e13
|
artikel
|
| 11 |
Dengue: a hidden threat in blood transfusions amidst Brazil's largest outbreak?
|
Almeida, Flávia Jacqueline
|
|
|
25 |
1 |
p. e10
|
artikel
|
| 12 |
Diane Edmund Griffin
|
Bagcchi, Sanjeet
|
|
|
25 |
1 |
p. 19
|
artikel
|
| 13 |
DoxyPEP: real-life effectiveness in a cohort of men who have sex with men in Milan, Italy
|
Raccagni, Angelo Roberto
|
|
|
25 |
1 |
p. e1-e3
|
artikel
|
| 14 |
DREAMS celebrates 10 years and looks to the future
|
Samarasekera, Udani
|
|
|
25 |
1 |
p. e15
|
artikel
|
| 15 |
Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial
|
Isa, Flonza
|
|
|
25 |
1 |
p. 52-67
|
artikel
|
| 16 |
Egypt eliminates malaria, while Sudan aims for control
|
Balakrishnan, Vijay Shankar
|
|
|
25 |
1 |
p. e16
|
artikel
|
| 17 |
Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations
|
Liu, Jingyi
|
|
|
25 |
1 |
p. e6-e7
|
artikel
|
| 18 |
Estimates of the burden of human rabies deaths and animal bites in India, 2022–23: a community-based cross-sectional survey and probability decision-tree modelling study
|
Thangaraj, Jeromie Wesley Vivian
|
|
|
25 |
1 |
p. 126-134
|
artikel
|
| 19 |
Fail to prepare, prepare to fail
|
Pope, Jessica
|
|
|
25 |
1 |
p. 23
|
artikel
|
| 20 |
First immunogenicity and safety data on live chikungunya vaccine in an endemic area
|
Freedman, David O
|
|
|
25 |
1 |
p. 11-13
|
artikel
|
| 21 |
Global health and pandemic preparedness at a crossroads
|
Kuppalli, Krutika
|
|
|
25 |
1 |
p. 16-18
|
artikel
|
| 22 |
Global measles cases up 20% in 2023
|
Kirby, Tony
|
|
|
25 |
1 |
p. e17
|
artikel
|
| 23 |
Global, regional, and national burden of upper respiratory infections and otitis media, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
|
|
|
|
25 |
1 |
p. 36-51
|
artikel
|
| 24 |
Heading in the direction of ending human deaths from dog-mediated rabies
|
Schneider, Maria Cristina
|
|
|
25 |
1 |
p. 13-14
|
artikel
|
| 25 |
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial
|
Harris, Victoria
|
|
|
25 |
1 |
p. 68-79
|
artikel
|
| 26 |
Highlights from ASTMH 2024
|
De Ambrogi, Marco
|
|
|
25 |
1 |
p. e14
|
artikel
|
| 27 |
Infectious disease surveillance update
|
McQuillan, Cahal
|
|
|
25 |
1 |
p. e21
|
artikel
|
| 28 |
Introducing our cover artist for 2025: Lillian Li
|
De Ambrogi, Marco
|
|
|
25 |
1 |
p. 18
|
artikel
|
| 29 |
Kinetics of neutralising antibodies against SARS-CoV-2 variants
|
Poletti, Piero
|
|
|
25 |
1 |
p. 8-9
|
artikel
|
| 30 |
Learning from AIDS for NCD control
|
Haslam, Elizabeth
|
|
|
25 |
1 |
p. 22
|
artikel
|
| 31 |
Maria Eugenia Toledo-Romani—doing a lot with the least
|
Kazi, Farooq
|
|
|
25 |
1 |
p. 20
|
artikel
|
| 32 |
Monkeypox virus isolation from longitudinal samples in 11 hospitalised patients
|
Callaby, Helen
|
|
|
25 |
1 |
p. e4-e5
|
artikel
|
| 33 |
Next-generation influenza vaccines based on mRNA technology
|
Isakova-Sivak, Irina
|
|
|
25 |
1 |
p. 2-3
|
artikel
|
| 34 |
Nipah virus research priorities: who sets them and for whom?
|
Hassan, Md Zakiul
|
|
|
25 |
1 |
p. e8
|
artikel
|
| 35 |
Novel and inexpensive skin test to detect tuberculosis
|
Bagcchi, Sanjeet
|
|
|
25 |
1 |
p. e18
|
artikel
|
| 36 |
Optimising vaccine immunogenicity in ageing populations: key strategies
|
Jiang, Guangzhen
|
|
|
25 |
1 |
p. e23-e33
|
artikel
|
| 37 |
Overcoming the global tuberculosis crisis with urgent country-level political and financial action
|
Sahu, Suvanand
|
|
|
25 |
1 |
p. 14-16
|
artikel
|
| 38 |
Prolonged detection of Oropouche virus RNA in whole blood samples
|
Colavita, Francesca
|
|
|
25 |
1 |
p. e11-e12
|
artikel
|
| 39 |
Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study
|
Russell, Timothy W
|
|
|
25 |
1 |
p. 80-93
|
artikel
|
| 40 |
Reflecting on lessons from the 2014–16 Ebola virus outbreak
|
The Lancet Infectious Diseases,
|
|
|
25 |
1 |
p. 1
|
artikel
|
| 41 |
Research in brief
|
Venkatesan, Priya
|
|
|
25 |
1 |
p. e22
|
artikel
|
| 42 |
Robert F Kennedy Junior—how concerned should we be?
|
Burki, Talha
|
|
|
25 |
1 |
p. e19-e20
|
artikel
|
| 43 |
Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in endemic areas of Brazil: interim results of a double-blind, randomised, placebo-controlled phase 3 trial in adolescents
|
Buerger, Vera
|
|
|
25 |
1 |
p. 114-125
|
artikel
|
| 44 |
Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple A/H3N2 strains with or without the B/Yamagata strain in US adults aged 50–75 years: a phase 1/2, open-label, randomised trial
|
Hsu, Denise
|
|
|
25 |
1 |
p. 25-35
|
artikel
|
| 45 |
SARS-CoV-2 antivirals and post-COVID-19 condition
|
Al-Aly, Ziyad
|
|
|
25 |
1 |
p. 6-8
|
artikel
|
| 46 |
Shorter antibiotic courses for respiratory tract infections
|
Tariq, Javeria
|
|
|
25 |
1 |
p. 10-11
|
artikel
|
| 47 |
Spreading awareness about HIV transmission
|
Bagcchi, Sanjeet
|
|
|
25 |
1 |
p. 24
|
artikel
|
| 48 |
The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review
|
Kuijpers, Suzanne M E
|
|
|
25 |
1 |
p. 94-113
|
artikel
|
| 49 |
Weighing up monoclonals and vaccination against COVID-19
|
Bauer, David L V
|
|
|
25 |
1 |
p. 5-6
|
artikel
|
Tijdschrift beschrijving